The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. (Q40399567)

20 September 2017

title

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. (English)

1 reference

20 September 2017

Gregory J Gores

1 reference

20 September 2017

Alex A Adjei

1 reference

20 September 2017

Chunrong Yu

1 reference

20 September 2017

Laura M Bruzek

1 reference

20 September 2017

Xue Wei Meng

1 reference

20 September 2017

Christopher A Carter

1 reference

20 September 2017

Scott H Kaufmann

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

page(s)

6861-6869

1 reference

Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

A genome-based strategy uncovers frequent BRAF mutations in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208841

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208841

1 reference

Dimensions Publication ID

20 September 2017

1053064977

0 references

1 reference